康惠制药: 康惠制药关于控股子公司停产的公告

Group 1 - The core point of the announcement is that Shaanxi Kanghui Pharmaceutical Co., Ltd. has decided to suspend production at its subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. to reduce losses and protect shareholder interests [1] - The suspension is due to intensified market competition and a continuous decline in product sales margins, leading to ongoing losses for Shaanxi Youbang [1][3] - The company plans to assess market conditions to determine whether to resume production in the future [1] Group 2 - Shaanxi Youbang's total assets accounted for 16.91% of the company's most recent audited total assets, and its revenue represented 1.42% of the consolidated revenue for the year 2024 [4] - The net profit for Shaanxi Youbang in 2024 was -52.51 million yuan, which impacted the company's most recent audited net profit by -26.78 million yuan, accounting for 29.88% of the company's net profit [4] - The suspension is expected to help the company avoid further losses and reduce operational costs, aligning with the company's strategic development direction [3][4]